Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
เนื้อหาจัดทำโดย Proactive Investors เนื้อหาพอดแคสต์ทั้งหมด รวมถึงตอน กราฟิก และคำอธิบายพอดแคสต์ได้รับการอัปโหลดและจัดหาให้โดยตรงจาก Proactive Investors หรือพันธมิตรแพลตฟอร์มพอดแคสต์ของพวกเขา หากคุณเชื่อว่ามีบุคคลอื่นใช้งานที่มีลิขสิทธิ์ของคุณโดยไม่ได้รับอนุญาต คุณสามารถปฏิบัติตามขั้นตอนที่แสดงไว้ที่นี่ https://th.player.fm/legal
Player FM - แอป Podcast
ออฟไลน์ด้วยแอป Player FM !
ออฟไลน์ด้วยแอป Player FM !
Tonix Pharmaceuticals CEO Discusses New Long Covid Report and Its Implications
MP3•หน้าโฮมของตอน
Manage episode 432634901 series 2891889
เนื้อหาจัดทำโดย Proactive Investors เนื้อหาพอดแคสต์ทั้งหมด รวมถึงตอน กราฟิก และคำอธิบายพอดแคสต์ได้รับการอัปโหลดและจัดหาให้โดยตรงจาก Proactive Investors หรือพันธมิตรแพลตฟอร์มพอดแคสต์ของพวกเขา หากคุณเชื่อว่ามีบุคคลอื่นใช้งานที่มีลิขสิทธิ์ของคุณโดยไม่ได้รับอนุญาต คุณสามารถปฏิบัติตามขั้นตอนที่แสดงไว้ที่นี่ https://th.player.fm/legal
Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, recently joined Steve Darling from Proactive to discuss the implications of a groundbreaking report from the US National Academies of Sciences, Engineering, and Medicine on long Covid. The report defines long Covid as a chronic condition encompassing multiple diagnosable disorders, thus paving the way for better understanding and treatment approaches. A particularly significant finding in the report is the acknowledgment that fibromyalgia can now be diagnosed in patients with long Covid, which eliminates previous diagnostic uncertainties. This development is especially beneficial for Tonix Pharmaceuticals, as the company is advancing TNX-102 SL, a drug designed to treat fibromyalgia. Dr. Lederman pointed out that this new diagnostic clarity could substantially broaden the addressable market for TNX-102 SL, which already targets approximately 10 million American adults diagnosed with fibromyalgia. Tonix Pharmaceuticals is in the final stages of developing TNX-102 SL, having received FDA Fast Track designation in recognition of its significant potential. The company has completed two statistically significant studies and is preparing a new drug application for submission. Dr. Lederman, who has nearly 30 years of experience researching fibromyalgia, emphasized the potential impact of this report on the estimated 14 million Americans suffering from long Covid. This new diagnostic criterion could enable these individuals to access effective treatments for fibromyalgia, representing a significant advancement in patient care. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #TonixPharmaceuticals, #SethLederman, #LongCovid, #Fibromyalgia, #NationalAcademies, #USScience, #TNX102SL, #DrugDevelopment, #FDA, #FastTrack, #Pharmaceuticals, #Health, #MedicalResearch, #Covid19, #ChronicIllness, #Medicine, #Healthcare, #ScientificResearch, #NewDrugApplication, #FibromyalgiaTreatment#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 ตอน
MP3•หน้าโฮมของตอน
Manage episode 432634901 series 2891889
เนื้อหาจัดทำโดย Proactive Investors เนื้อหาพอดแคสต์ทั้งหมด รวมถึงตอน กราฟิก และคำอธิบายพอดแคสต์ได้รับการอัปโหลดและจัดหาให้โดยตรงจาก Proactive Investors หรือพันธมิตรแพลตฟอร์มพอดแคสต์ของพวกเขา หากคุณเชื่อว่ามีบุคคลอื่นใช้งานที่มีลิขสิทธิ์ของคุณโดยไม่ได้รับอนุญาต คุณสามารถปฏิบัติตามขั้นตอนที่แสดงไว้ที่นี่ https://th.player.fm/legal
Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, recently joined Steve Darling from Proactive to discuss the implications of a groundbreaking report from the US National Academies of Sciences, Engineering, and Medicine on long Covid. The report defines long Covid as a chronic condition encompassing multiple diagnosable disorders, thus paving the way for better understanding and treatment approaches. A particularly significant finding in the report is the acknowledgment that fibromyalgia can now be diagnosed in patients with long Covid, which eliminates previous diagnostic uncertainties. This development is especially beneficial for Tonix Pharmaceuticals, as the company is advancing TNX-102 SL, a drug designed to treat fibromyalgia. Dr. Lederman pointed out that this new diagnostic clarity could substantially broaden the addressable market for TNX-102 SL, which already targets approximately 10 million American adults diagnosed with fibromyalgia. Tonix Pharmaceuticals is in the final stages of developing TNX-102 SL, having received FDA Fast Track designation in recognition of its significant potential. The company has completed two statistically significant studies and is preparing a new drug application for submission. Dr. Lederman, who has nearly 30 years of experience researching fibromyalgia, emphasized the potential impact of this report on the estimated 14 million Americans suffering from long Covid. This new diagnostic criterion could enable these individuals to access effective treatments for fibromyalgia, representing a significant advancement in patient care. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #TonixPharmaceuticals, #SethLederman, #LongCovid, #Fibromyalgia, #NationalAcademies, #USScience, #TNX102SL, #DrugDevelopment, #FDA, #FastTrack, #Pharmaceuticals, #Health, #MedicalResearch, #Covid19, #ChronicIllness, #Medicine, #Healthcare, #ScientificResearch, #NewDrugApplication, #FibromyalgiaTreatment#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 ตอน
All episodes
×ขอต้อนรับสู่ Player FM!
Player FM กำลังหาเว็บ